Nebenwirkungen · Olanzapine Glenmark Europe
Olanzapine Glenmark Europe 20 mg orodispersible tablets · Abschnitt 4.8 · PDF-Seite 56
HOS-211311 · Präparat HOS-154655
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients. Clinically significant weight gain (≥ 7 %) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T01:00:00Z · SHA-256 3385ebe3ca7a68a60feca3a8291940e24a6aa51ddf5c7200424a88297e096b8b · Passage a67d5f9a04c8350bdcdee6d5dff773b6c74ceb0bf2b054ce943b8efce36241ec · Zeichen 12392–12991 im Abschnitt